Samsung Bioepis will use CMOs to make Ontruzant if it is approved

By Gareth Macdonald contact

- Last updated on GMT

Samsung Bioepis will use CMOs to make Ontruzant if it is approved

Related tags: European commission

Samsung Bioepis will use contractors to make its candidate Herceptin biosimilar Ontruzant if it goes on to be approved in Europe.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on Ontruzant (traztuzumab) this week​.

The committee recommended it be approved for the treatment of various breast and gastric cancers.

If the European Commission (EC) decided to follow the recommendation, Samsung Bioepis development partner MSD, known as Merck in the US and Canada, will commercialize the drug in European markets an agreement inked in February 2013.

Under the agreement Samsung Bioepis is responsible for preclinical and clinical development, process development and manufacturing.

However, production will be carried out by third parties according to a Samsung spokesman who told us the firm’s strategy is to “use multiple contract manufacturing organizations, in order to ensure the reliable supply of our products​.”

Ontruzant, like Roche’s originator product, is a monoclonal antibody.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars